세계의 전자 약물 전달 장치 시장 : 규모, 점유율, 동향 분석(제품별, 용도별, 지역별), 부문별 예측(2025-2030년)

Electronic Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Implantable Drug Delivery Devices, Smart Metered Dose Inhalers), By Application (Diabetes, Oncology), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,275,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,666,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,447,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

전자 약물 전달 장치 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 전자 약물 전달 장치 시장 규모는 2030년까지 995억 달러에 이를 것으로 예측되며, 2025년부터 2030년까지의 CAGR은 8.14%를 나타낼 것으로 예측됩니다.

이 성장은 노인 인구 증가와 만성 질환의 만연, 맞춤형 의료에 대한 의식 증가, 홈 의료의 인기, 디지털 기술의 통합 등에 기인하고 있습니다. 예를 들어, AptarGroup, Inc. Medical의 자동 주사기, 펜형 주사기, 특수 전달 시스템과 같은 고급 약물전달 시스템과 통합되었습니다.

환자가 집에서 건강 상태를 관리하는 것을 선호하기 때문에 안전하고 효과적이고 간단한 가정 치료를 가능하게 하는 약물전달 장치에 대한 수요가 높아지고 있습니다. 인슐린 펌프, 자동 주사기, 웨어러블 주입 펌프, 사전 충전 주사기와 같은 장치는 환자가 최소한의 도움으로 약물을 자가 투여할 수 있어 편리함과 자율성을 모두 제공하기 때문에 가정 의료에서 필수적인 도구가 되고 있습니다. 혁신적인 PEEK 바이오소재 솔루션으로 유명한 Victrex는 2023년 10월 의약품 배송 및 의약품 접촉 애플리케이션을 위해 특별히 설계된 첨단 제품인 VICTREX PC101 등급을 발표했습니다.

게다가, 전자 약물 전달 장치 시장의 기술 동향은 보다 높은 정밀도, 개인화, 환자의 편의성에 대한 요구에 힘입어 급속히 발전하고 있습니다. 새로운 트렌드 중 일부는 디지털 건강 기술, 웨어러블 약물 전달 장치의 통합, 그리고 미세유체학의 사용을 포함합니다. 정밀의료의 대두도 기술 혁신을 뒷받침하고 있습니다.

전자 약물 전달 장치 시장 : 분석 개요

• 제품별로는 임베디드 약물전달 장치가 부작용의 경감, 약물 방출의 제어, 국소적인 치료가 가능하기 때문에 2024년에는 33.0%의 최대 매출 점유율로 시장을 독점했습니다.
• 용도별로는 당뇨병 분야가 2024년에 최대의 수익 점유율을 차지했습니다. 이것은 당뇨병의 높은 유병률과 환자수 증가, 당뇨병 치료에 있어서의 기술 진보, 시장 수요 증가, 상환 지원에 의한 것입니다.
• 지역별로는 북미가 2024년에 43.4% 이상의 최대 수익 점유율을 차지했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 전자 약물전달 장치 시장 : 변동 요인 및 경향 및 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련, 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 주요 기술 동향
• 주요 브랜드
• 파이프라인 분석
• 전자 약물전달 장치 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 전자 약물전달 장치 시장 : 제품별 추정 및 동향 분석

• 부문 대시보드
• 전자 약물 전달 장치 시장 : 제품별 변동 분석
• 전자 약물 전달 장치 시장 : 제품별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
• 스마트 주입 펌프(수액 시스템)
• 스마트 정량 흡입기(흡입 장치)
• 이식형 약물전달 장치

제5장 전자 약물 전달 장치 시장 : 용도별 추정 및 동향 분석

• 부문 대시보드
• 전자 약물 전달 장치 시장 : 용도별 변동 분석
• 전자 약물 전달 장치 시장 : 용도별 전망
• 시장 규모 예측과 동향 분석(2018-2030년)
• 당뇨병
• 호흡기 질환
• 종양학
• 심장병학
• 기타

제6장 전자 약물 전달 장치 시장 : 지역별 추정 및 동향 분석

• 지역 대시보드
• 전자 약물 전달 장치 시장 : 지역별 변동 분석
• 전자 약물 전달 장치 시장 : 지역별 추정 및 동향 분석
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 시장 진출기업의 분류
• 주요 기업 프로파일
  • Medtronic plc
  • Insulet Corporation
  • Becton, Dickinson and Company
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
  • Novo Nordisk A/S
  • Sanofi SA
  • Eli, Lilly and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries
  • Phillips-Medisize, LLC
  • West Pharmaceutical Services, Inc.
  • Gerresheimer AG
  • Nemera Group
  • SHL Group
  • Owen Mumford
  • Haselmeier AG
  • ICU Medical
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sparsha Pharma International
  • Baxter International, Inc.
  • Fresenius Kabi AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Novartis AG
  • AptarGroup, Inc.
  • Teleflex Incorporates
  • Abbott Laboratories

SHW

영문 목차

영문목차

Electronic Drug Delivery Devices Market Growth & Trends:

The global electronic drug delivery devices market size is anticipated to reach USD 99.5 billion by 2030 and is anticipated to grow at a CAGR of 8.14% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the increasing the growing geriatric population and prevalence of chronic diseases, increasing awareness for personalized medicine, rising preference for home healthcare, and the integration of digital technologies. For instance, in June 2024, AptarGroup, Inc. collaborated with SHL Medical to integrate Aptar Digital Health's SaMD platform with SHL Medical's advanced drug delivery systems, such as autoinjectors, pen injectors, and specialty delivery systems.

As patients are increasingly preferring to manage their health conditions at home, there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering both convenience and autonomy. For instance, in October 2023, Victrex plc, known for its innovative PEEK biomaterial solutions, introduced an advanced product, the VICTREX PC101 grade, specifically designed for drug delivery and pharmaceutical contact applications. This launch aligns with the growing trend of utilizing drug delivery devices in homecare environments, enhancing accessibility for patients seeking innovative solutions.

Moreover, technology trends in the electronic drug delivery devices market are rapidly advancing, driven by the need for greater precision, personalization, and patient convenience. Some of the new trends include the integration of digital health technologies, wearable drug delivery devices, and the use of microfluidics. The rise of precision medicine is also driving innovation. The devices are being tailored to the individual's genetic makeup, condition, or specific therapeutic needs, ensuring better outcomes and fewer side effects.

Electronic Drug Delivery Devices Market Report Highlights:

• Based on product, the implantable drug delivery devices segment dominated the market with the largest revenue share of 33.0% in 2024 owing to reduced side effects, controlled drug release, and their ability to provide localized treatment.
• Based on application, the diabetes segment accounted for the largest revenue share in 2024 due to its high prevalence and growing patient population, technological advancements in diabetes care, growing market demand, and reimbursement support.
• Based on region, North America held the largest revenue share of over 43.4% in 2024. This can be attributed to technological advancements, an increasing prevalence of chronic diseases, and rising demand for patient-centric drug delivery solutions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Electronic Drug Delivery Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases and growing geriatric population
    • 3.2.1.2. Rising preference for home healthcare
    • 3.2.1.3. Integration of digital technologies and growing awareness of personalized medications
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced drug delivery devices
    • 3.2.2.2. Limited patient awareness and device-related complications
• 3.3. Key Technology Trends
• 3.4. Key Brands
• 3.5. Pipeline Analysis
• 3.6. Electronic Drug Delivery Devices Market Analysis Tools
  • 3.6.1. Industry Analysis - Porter's
    • 3.6.1.1. Bargaining power of suppliers
    • 3.6.1.2. Bargaining power of buyers
    • 3.6.1.3. Threat of substitutes
    • 3.6.1.4. Threat of new entrants
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL Analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Economic landscape
    • 3.6.2.3. Social landscape
    • 3.6.2.4. Technological landscape
    • 3.6.2.5. Environmental landscape
    • 3.6.2.6. Legal landscape

Chapter 4. Electronic Drug Delivery Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Electronic Drug Delivery Devices Market: Product Movement Analysis
• 4.3. Electronic Drug Delivery Devices Market by Product Outlook (Revenue, USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Smart Infusion Pumps (Infusion Systems)
  • 4.5.1. Smart Infusion Pumps (Infusion Systems) Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.5.1.1. Non-biologic Smart Infusion Systems
      • 4.5.1.1.1. Non-biologic Smart Infusion Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.5.1.2. Biologic Smart Infusion Systems
      • 4.5.1.2.1. Biologic Smart Infusion Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
        • 4.5.1.2.1.1. Smart Infusion Insulin Pumps
          • 4.5.1.2.1.1.1. Smart Infusion Insulin Pumps Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
        • 4.5.1.2.1.2. Others
          • 4.5.1.2.1.2.1. Others Market Revenue Estimated and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 4.6. Smart Metered Dose Inhalers (Inhalation Devices)
  • 4.6.1. Smart Metered Dose Inhalers (Inhalation Devices) Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 4.7. Implantable Drug Delivery Devices
  • 4.7.1. Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.7.1.1. Biologic Implantable Drug Delivery Devices
      • 4.7.1.1.1. Biologic Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.7.1.2. Non-biologic Implantable Drug Delivery Devices
      • 4.7.1.2.1. Non-biologic Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 5. Electronic Drug Delivery Devices Market: Application Estimated & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Electronic Drug Delivery Devices Market: Application Movement Analysis
• 5.3. Electronic Drug Delivery Devices Market by Application Outlook (Revenue, USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Diabetes
  • 5.5.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.6. Respiratory Diseases
  • 5.6.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.7. Oncology
  • 5.7.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.8. Cardiology
  • 5.8.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Electronic Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional Electronic Drug Delivery Devices Market Movement Analysis
• 6.3. Electronic Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Product
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Mexico Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Europe
  • 6.6.1. Europe Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. UK Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Germany Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. France Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. Italy Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Spain Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.7. Denmark
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Denmark Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Competitive Scenario
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Reimbursement scenario
    • 6.6.8.5. Sweden Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.9. Norway
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Competitive Scenario
    • 6.6.9.3. Regulatory Framework
    • 6.6.9.4. Reimbursement scenario
    • 6.6.9.5. Norway Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. Japan
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Japan Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. China Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. India Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. South Korea Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.6. Australia
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Reimbursement scenario
    • 6.7.6.5. Australia Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Reimbursement scenario
    • 6.7.7.5. Thailand Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.8.2. Brazil
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. Brazil Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Argentina Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.9. Middle East & Africa
  • 6.9.1. Middle East & Africa Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.2. South Africa
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Reimbursement scenario
    • 6.9.2.5. South Africa Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Reimbursement scenario
    • 6.9.3.5. Saudi Arabia Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Competitive Scenario
    • 6.9.4.3. Regulatory Framework
    • 6.9.4.4. Reimbursement scenario
    • 6.9.4.5. UAE Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key Country Dynamics
    • 6.9.5.2. Competitive Scenario
    • 6.9.5.3. Regulatory Framework
    • 6.9.5.4. Reimbursement scenario
    • 6.9.5.5. Kuwait Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Medtronic plc
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Insulet Corporation
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Becton, Dickinson and Company
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Tandem Diabetes Care, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Ypsomed AG
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Novo Nordisk A/S
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Sanofi S.A.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Eli, Lilly and Company
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. AstraZeneca plc
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. GlaxoSmithKline plc
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Boehringer Ingelheim International GmbH
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Pfizer, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. Teva Pharmaceutical Industries
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. Phillips-Medisize, LLC
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives
  • 7.2.15. West Pharmaceutical Services, Inc.
    • 7.2.15.1. Company overview
    • 7.2.15.2. Financial performance
    • 7.2.15.3. Product benchmarking
    • 7.2.15.4. Strategic initiatives
  • 7.2.16. Gerresheimer AG
    • 7.2.16.1. Company Overview
    • 7.2.16.2. Financial performance
    • 7.2.16.3. Product benchmarking
    • 7.2.16.4. Strategic initiatives
  • 7.2.17. Nemera Group
    • 7.2.17.1. Company overview
    • 7.2.17.2. Financial performance
    • 7.2.17.3. Product benchmarking
    • 7.2.17.4. Strategic initiatives
  • 7.2.18. SHL Group
    • 7.2.18.1. Company overview
    • 7.2.18.2. Financial performance
    • 7.2.18.3. Product benchmarking
    • 7.2.18.4. Strategic initiatives
  • 7.2.19. Owen Mumford
    • 7.2.19.1. Company overview
    • 7.2.19.2. Financial performance
    • 7.2.19.3. Product benchmarking
    • 7.2.19.4. Strategic initiatives
  • 7.2.20. Haselmeier AG
    • 7.2.20.1. Company overview
    • 7.2.20.2. Financial performance
    • 7.2.20.3. Product benchmarking
    • 7.2.20.4. Strategic initiatives
  • 7.2.21. ICU Medical
    • 7.2.21.1. Company overview
    • 7.2.21.2. Financial performance
    • 7.2.21.3. Product benchmarking
    • 7.2.21.4. Strategic initiatives
  • 7.2.22. Hisamitsu Pharmaceutical Co., Inc.
    • 7.2.22.1. Company overview
    • 7.2.22.2. Financial performance
    • 7.2.22.3. Product benchmarking
    • 7.2.22.4. Strategic initiatives
  • 7.2.23. Sparsha Pharma International
    • 7.2.23.1. Company overview
    • 7.2.23.2. Financial performance
    • 7.2.23.3. Product benchmarking
    • 7.2.23.4. Strategic initiatives
  • 7.2.24. Baxter International, Inc.
    • 7.2.24.1. Company overview
    • 7.2.24.2. Financial performance
    • 7.2.24.3. Product benchmarking
    • 7.2.24.4. Strategic initiatives
  • 7.2.25. Fresenius Kabi AG
    • 7.2.25.1. Company overview
    • 7.2.25.2. Financial performance
    • 7.2.25.3. Product benchmarking
    • 7.2.25.4. Strategic initiatives
  • 7.2.26. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 7.2.26.1. Company overview
    • 7.2.26.2. Financial performance
    • 7.2.26.3. Product benchmarking
    • 7.2.26.4. Strategic initiatives
  • 7.2.27. Novartis AG
    • 7.2.27.1. Company overview
    • 7.2.27.2. Financial performance
    • 7.2.27.3. Product benchmarking
    • 7.2.27.4. Strategic initiatives
  • 7.2.28. AptarGroup, Inc.
    • 7.2.28.1. Company overview
    • 7.2.28.2. Financial performance
    • 7.2.28.3. Product benchmarking
    • 7.2.28.4. Strategic initiatives
  • 7.2.29. Teleflex Incorporates
    • 7.2.29.1. Company overview
    • 7.2.29.2. Financial performance
    • 7.2.29.3. Product benchmarking
    • 7.2.29.4. Strategic initiatives
  • 7.2.30. Abbott Laboratories
    • 7.2.30.1. Company overview
    • 7.2.30.2. Financial performance
    • 7.2.30.3. Product benchmarking
    • 7.2.30.4. Strategic initiatives

관련자료